10.04
Schlusskurs vom Vortag:
$10.29
Offen:
$10.29
24-Stunden-Volumen:
2.33M
Relative Volume:
0.59
Marktkapitalisierung:
$2.86B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-125.04M
KGV:
-12.25
EPS:
-0.82
Netto-Cashflow:
$-122.99M
1W Leistung:
+4.48%
1M Leistung:
+196.49%
6M Leistung:
+487.78%
1J Leistung:
+405.08%
Erasca Inc Stock (ERAS) Company Profile
Firmenname
Erasca Inc
Sektor
Branche
Telefon
(858) 465-6511
Adresse
3115 MERRYFIELD ROW, SAN DIEGO
Vergleichen Sie ERAS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
ERAS
Erasca Inc
|
10.06 | 2.92B | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-16 | Eingeleitet | Stifel | Buy |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | Eingeleitet | Raymond James | Outperform |
| 2024-11-18 | Eingeleitet | Jefferies | Buy |
| 2024-03-11 | Eingeleitet | CapitalOne | Overweight |
| 2024-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-03-30 | Eingeleitet | Mizuho | Buy |
| 2023-02-24 | Eingeleitet | Goldman | Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Erasca Inc Aktie (ERAS) Neueste Nachrichten
Erasca stock hits 52-week high at 10.46 USD By Investing.com - Investing.com Nigeria
Erasca Announces Major Underwritten Public Equity Offering - TipRanks
Erasca, Inc. Announces Upsized Public Offering of Common Stock - TradingView — Track All Markets
Erasca raises $225M to sharpen RAS oncology focus - BioWorld MedTech
Latham & Watkins Advises Erasca in Upsized US$225 Million Offering of Common Stock - Latham & Watkins LLP
Erasca prices $225M stock offering at $10 per share - MSN
A trio of biotechs targets $500M+ offerings - Endpoints News
Erasca stock hits 52-week high at 10.46 USD - Investing.com
Top 2 Tech Stocks That Are Ticking Portfolio Bombs - Benzinga
Erasca Announces Pricing of Upsized Public Offering of Common Stock - The Manila Times
Erasca, Inc. Announces Pricing of $225 Million Public Offering of Common Stock - Quiver Quantitative
Cancer drug developer Erasca raises $225M in stock sale - Stock Titan
Erasca Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewswire Inc.
Top 2 Industrials Stocks That May Collapse In Q1 - Benzinga
Netflix, Erasca, Kraft Heinz And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Erasca plans to raise $150 million in public stock offering By Investing.com - Investing.com Nigeria
Erasca Announces $150 Million Public Offering; Stock Down - Nasdaq
Erasca Stock Pre-Market (-8.3%) : Announces $150M Public Stock Offering - Trefis
Erasca plans $150M public stock offering - MSN
Erasca stock falls after announcing $150 million public offering - Investing.com
Erasca announces proposed public offering of $150 million of common stock - marketscreener.com
Erasca (ERAS) Stock Slides After The Bell: Here's Why - Benzinga
Erasca (ERAS) Announces $150M Public Offering to Fund Cancer Research - Intellectia AI
Erasca reports preliminary year-end cash and securities of $341.8 million - Investing.com
Erasca, Inc. Announces Proposed Public Offering of $150 Million in Common Stock - Quiver Quantitative
Erasca Announces Proposed Public Offering of $150 Million of Common Stock - The Manila Times
Cancer drug developer Erasca plans $150M stock sale to fund R&D - Stock Titan
Erasca (ERAS) Soars 42% on Bullish Rating, PT Upgrade - Finviz
Erasca (ERAS) touches 3-year high as 4 analysts go bullish; gets 267% PT hike - MSN
Do Early ERAS-0015 Data Reframe Erasca’s (ERAS) Ambitions in RAS-Targeted Oncology? - simplywall.st
Erasca stock surges 42% in a week: Here's what you should know - MSN
Erasca (ERAS) Valuation Comes Into Focus After Early ERAS-0015 Data At JP Morgan Healthcare Conference - simplywall.st
Erasca Offers $7.50 Put Option, Attracting Investor Interest - Intellectia AI
Erasca (ERAS) Touches 3-Year High as 4 Analysts Go Bullish; Gets 267% PT Hike - Finviz
Erasca price target raised to $11 from $5 at Piper Sandler - TipRanks
Erasca Stock Surges 42% in a Week: Here's What You Should Know - Finviz
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape - PR Newswire
HC Wainwright Has Strong Estimate for Erasca FY2027 Earnings - Defense World
Winners Losers: What is AXIS Capital Holdings Limiteds debt to equity ratioAnalyst Downgrade & Fast Gain Stock Tips - baoquankhu1.vn
Assessing Erasca (ERAS) Valuation After Encouraging Early ERAS-0015 Data At JP Morgan Conference - Yahoo Finance
Erasca Rallies Amid Acquisition Talks and Positive Price Target Revisions - StocksToTrade
Clear Street Elevates Erasca: Price Target Stands Tall at $11 - timothysykes.com
FY2027 Earnings Forecast for Erasca Issued By HC Wainwright - MarketBeat
Erasca (ERAS) Is Up 60.7% After Early ERAS-0015 Data Highlights Pan-RAS Franchise Ambitions - Yahoo Finance
Erasca (ERAS) Hits Fresh High Anew as Firm Gets up to 267% PT Hike - Insider Monkey
10 Stock With Eye-Popping Gains; 5 Are on Fresh Highs - Insider Monkey
Erasca stock hits 52-week high at 8.33 USD By Investing.com - Investing.com Nigeria
Erasca (NASDAQ:ERAS) Trading Up 7.7% Following Analyst Upgrade - Defense World
Erasca (ERAS) Price Target Increased by 30.91% to 6.53 - Nasdaq
Erasca stock jumps 10% as Wall Street lifts targets to $11 on ERAS-0015 data - TechStock²
Erasca stock hits 52-week high at 8.33 USD - Investing.com
Finanzdaten der Erasca Inc-Aktie (ERAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):